Browse drugs

…med a post hoc analysis of the 52-week, double-blind, Effect of Indacaterol Glycopyrronium versus Fluticasone Salmeterol on COPD Exacerbations trial that …

…) for preventing exacerbations. Our findings indicate that LABA+LAMA is superior to LABA+ICS in preventing moderate to severe exacer…

…ating therapy with LABA-ICS inhalers may be more effective than LABA-LAMA inhalers among patients with multiple exacerbations, particular…

…er triple therapy (SITT) consisting of beclometasone/formoterol/glycopyrronium (BDP/FF/G) in patients with asthma has been demonstrated in ran…

…acting β2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and triple therapy (ICS/LABA/LAMA), on exacerbation rates and …

…atients started the deprescribing pathway. So far, 100% (n= 11) theophylline, 98% (n= 45) montelukast, 82% (n= 49) LAMA inhalers, 85% (n= 13…

…meter (MMAD) were compared across all active components.Results BDP/FF/GB pMDI demonstrated substantially greater eFPF vs either BUD/FF/GB pMD…

…A long-acting muscarinic antagonist (LAMA) may be added to medium-/high-dose inhaled corticosteroid (ICS)…

…equent 8 months (period 4–12 months) was of 30.5% and 24.1%, in TRIMARAN and TRIGGER, respectively (RR of 0.695, 95% CI 0.501–0.965, p=0…

… 0/44 (0.0%) 0/44 (0.0%) NA 50/230 (21.7%) 36/141 (25.5%) 0.475 Omalizumab NA NA NA 0/44 (0.0%) 0/44 (0.0%) NA 36/236 (15.3%) 16/141 (11.3…

…mainly treated with bronchodilators (long-acting beta-agonists (LABA) and/or long-acting muscarinic antagonists (LAMA)) to reduce sy…